AP706A - Injectable quinolone formulations. - Google Patents

Injectable quinolone formulations. Download PDF

Info

Publication number
AP706A
AP706A APAP/P/1996/000898A AP9600898A AP706A AP 706 A AP706 A AP 706A AP 9600898 A AP9600898 A AP 9600898A AP 706 A AP706 A AP 706A
Authority
AP
ARIPO
Prior art keywords
solution
formulation
danofloxacin
added
pvp
Prior art date
Application number
APAP/P/1996/000898A
Other languages
English (en)
Other versions
AP9600898A0 (en
Inventor
Wayne Alan Boettner
Peter Connor Canning
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600898A0 publication Critical patent/AP9600898A0/xx
Application granted granted Critical
Publication of AP706A publication Critical patent/AP706A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1996/000898A 1995-12-21 1996-12-19 Injectable quinolone formulations. AP706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (2)

Publication Number Publication Date
AP9600898A0 AP9600898A0 (en) 1997-01-31
AP706A true AP706A (en) 1998-12-04

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000898A AP706A (en) 1995-12-21 1996-12-19 Injectable quinolone formulations.

Country Status (42)

Country Link
US (1) US5811130A (ja)
EP (1) EP0868183B1 (ja)
JP (1) JP3416145B2 (ja)
KR (1) KR100402570B1 (ja)
CN (1) CN1104899C (ja)
AP (1) AP706A (ja)
AR (1) AR005147A1 (ja)
AT (1) ATE212551T1 (ja)
AU (1) AU709474B2 (ja)
BG (1) BG63933B1 (ja)
BR (1) BR9612230A (ja)
CA (1) CA2239352C (ja)
CO (1) CO4480098A1 (ja)
CZ (1) CZ293747B6 (ja)
DE (1) DE69618987T2 (ja)
DK (1) DK0868183T3 (ja)
DZ (1) DZ2146A1 (ja)
EG (1) EG24071A (ja)
ES (1) ES2167609T3 (ja)
GT (1) GT199600098A (ja)
HR (1) HRP960607B1 (ja)
HU (1) HU227918B1 (ja)
IL (1) IL124454A (ja)
IS (1) IS2010B (ja)
MA (1) MA24035A1 (ja)
MX (1) MX9805026A (ja)
MY (1) MY117109A (ja)
NO (1) NO315734B1 (ja)
NZ (2) NZ320545A (ja)
OA (1) OA10697A (ja)
PE (1) PE25798A1 (ja)
PL (1) PL186795B1 (ja)
PT (1) PT868183E (ja)
RS (1) RS49523B (ja)
RU (1) RU2141827C1 (ja)
SI (1) SI0868183T1 (ja)
SK (1) SK284412B6 (ja)
TN (1) TNSN96163A1 (ja)
TW (1) TW449475B (ja)
UA (1) UA56151C2 (ja)
WO (1) WO1997023217A1 (ja)
ZA (1) ZA9610780B (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
CA2433037C (en) * 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
BR0312111A (pt) * 2002-06-26 2005-03-29 Pharmacia Corp Formulação estável, lìquida, parenteral de parecoxib
RU2007104026A (ru) * 2004-07-02 2008-08-10 Дайити Фармасьютикал Ко., Лтд. (JP) Содержащая хинолон лекарственная композиция
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2594272B1 (en) * 2005-05-18 2018-07-11 Horizon Orphan LLC Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
CA2641827A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
HUE050147T2 (hu) 2008-10-07 2020-11-30 Horizon Orphan Llc Tüdõgyulladás csökkentése levofloxacin belélegzése útján
NO2344129T3 (ja) 2008-10-07 2018-07-21
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
MX2019009572A (es) * 2017-02-13 2019-10-02 Bayer Animal Health Gmbh Composicion liquida que contiene pradofloxacina.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337231A2 (de) * 1988-04-15 1989-10-18 Bayer Ag i.m. Injektionsformen von Gyrase-Inhibitoren
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0470667A1 (en) * 1990-08-10 1992-02-12 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition containing a 4-quinolone derivative complexed with a divalent metal ion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
CA2072366C (en) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Carboxylic acid-metal ion-acid complexes
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337231A2 (de) * 1988-04-15 1989-10-18 Bayer Ag i.m. Injektionsformen von Gyrase-Inhibitoren
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0470667A1 (en) * 1990-08-10 1992-02-12 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Composition containing a 4-quinolone derivative complexed with a divalent metal ion

Also Published As

Publication number Publication date
DE69618987T2 (de) 2002-11-21
CA2239352A1 (en) 1997-07-03
IS4755A (is) 1998-05-25
RU2141827C1 (ru) 1999-11-27
CZ293747B6 (cs) 2004-07-14
HUP9903726A3 (en) 2001-01-29
CZ193098A3 (cs) 1999-05-12
TW449475B (en) 2001-08-11
MX9805026A (es) 1998-09-30
UA56151C2 (uk) 2003-05-15
SK80798A3 (en) 1999-09-10
BG63933B1 (bg) 2003-07-31
MA24035A1 (fr) 1997-07-01
HUP9903726A2 (hu) 2000-04-28
NO982842D0 (no) 1998-06-19
KR100402570B1 (ko) 2003-12-18
OA10697A (en) 2001-05-04
ES2167609T3 (es) 2002-05-16
JP3416145B2 (ja) 2003-06-16
US5811130A (en) 1998-09-22
IL124454A (en) 2003-10-31
DK0868183T3 (da) 2002-03-25
EG24071A (en) 2008-05-11
WO1997023217A1 (en) 1997-07-03
BG102542A (en) 1999-06-30
HRP960607A2 (en) 1998-06-30
AP9600898A0 (en) 1997-01-31
SI0868183T1 (en) 2002-04-30
YU69096A (sh) 1999-06-15
KR19990076617A (ko) 1999-10-15
NZ320545A (en) 2000-03-27
CA2239352C (en) 2002-06-04
HU227918B1 (en) 2012-06-28
CN1205636A (zh) 1999-01-20
ZA9610780B (en) 1998-06-22
AU709474B2 (en) 1999-08-26
CO4480098A1 (es) 1997-07-09
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
DZ2146A1 (fr) 2002-10-23
BR9612230A (pt) 1999-07-13
GT199600098A (es) 1998-06-12
PE25798A1 (es) 1998-05-21
NO982842L (no) 1998-06-19
PL328001A1 (en) 1999-01-04
MY117109A (en) 2004-05-31
PT868183E (pt) 2002-06-28
ATE212551T1 (de) 2002-02-15
SK284412B6 (sk) 2005-03-04
IL124454A0 (en) 1998-12-06
PL186795B1 (pl) 2004-02-27
IS2010B (is) 2005-05-13
NO315734B1 (no) 2003-10-20
DE69618987D1 (de) 2002-03-14
JPH11501331A (ja) 1999-02-02
NZ501160A (en) 2001-10-26
TNSN96163A1 (fr) 2005-03-15
HRP960607B1 (en) 2002-06-30
AR005147A1 (es) 1999-04-14
AU7328996A (en) 1997-07-17
CN1104899C (zh) 2003-04-09
EP0868183B1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
AP706A (en) Injectable quinolone formulations.
CS199527B2 (en) Manufacturing process of the steady antibiotic agent
US4772460A (en) Method of reducing the swelling or pain associated with antibiotics compositions
AU594266B2 (en) Nicorandil-containing preparation for injection
EP0769951B1 (en) Long-acting oxytetracycline composition
EP1352654B1 (en) Famotidine injections
WO1996001634B1 (en) Long-acting oxytetracycline composition
US6110905A (en) Long-acting oxytetracycline composition
US4973591A (en) Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine
US20030153581A1 (en) Stabilized difloxacin injectable solution
US5063220A (en) Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine
CA1217425A (en) Oxytetracyclin-solutions
EP0640074B1 (en) Salts of a quinolone-carboxylic acid
WO2000072848A1 (en) Composition comprising (±)-5-ethyldihydro-5-(1-methylbutyl)-2-thioxo 4,6(1h,5h)-pyrimidinedione dissolved in 2,5-di-o-methyl-1,4:3,6-dianhydro-d-glucitol